#HELEN006

🆕
#HELEN006 trial:
weekly nab-paclitaxel with trastuzumab & pertuzumab showed a higher pCR (66.3%) 🆚 docetaxel + carboplatin (57.6%) in HER2-positive #eBC, with fewer severe side effects.
A potential new standard for neoadjuvant therapy❓
@oncoalert.bsky.social

thelancet.com/journals/lanon…

Is carbo needed for the neoadjuvant treatment of HER2+ BC? The #HELEN006 ph 3 trial randomized pts to TCHPx6 vs nabTHPx6. nabTHP had significantly higher pCR rate vs TCHP (66% vs 57%), with less toxicities. CompassHER-pCR trial ongoing to validate THP (x4) www.sciencedirect.com/science/arti...